# LUNG-MAP (NCT04173507)

> Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

No report yet. It can be ordered.

- Drugs tested: talazoparib plus avelumab
- Indication: STK11-mutated advanced non-squamous non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04173507
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions: Avelumab; Talazoparib; Talazoparib Tosylate
- Enrollment: 47
- Primary outcome: Objective Response Rate (ORR)
- Primary outcome: Disease Control Rate at 12 Weeks (DCR12)

## Indexed commentary on LUNG-MAP so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lung-map-nct04173507